These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 12473572)

  • 1. Targeting the mitochondria: an exciting new approach to myeloma therapy. Commentary re: N. J. Bahlis et al., Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin. Cancer Res., 8: 3658-3668, 2002.
    Dalton WS
    Clin Cancer Res; 2002 Dec; 8(12):3643-5. PubMed ID: 12473572
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent.
    Amadori S; Fenaux P; Ludwig H; O'dwyer M; Sanz M
    Curr Med Res Opin; 2005 Mar; 21(3):403-11. PubMed ID: 15811209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma.
    Wu KL; Beksac M; van Droogenbroeck J; Amadori S; Zweegman S; Sonneveld P
    Haematologica; 2006 Dec; 91(12):1722-3. PubMed ID: 17145617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma.
    Hussein MA; Saleh M; Ravandi F; Mason J; Rifkin RM; Ellison R
    Br J Haematol; 2004 May; 125(4):470-6. PubMed ID: 15142117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New drugs in multiple myeloma.
    Berenson JR; Yellin O
    Curr Opin Support Palliat Care; 2008 Sep; 2(3):204-10. PubMed ID: 18685422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trials referral resource. Clinical trials with arsenic trioxide.
    Murgo AJ; McBee WL; Cheson BD
    Oncology (Williston Park); 2000 Feb; 14(2):206, 211, 215-6 passim. PubMed ID: 10736809
    [No Abstract]   [Full Text] [Related]  

  • 7. Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid.
    Campbell RA; Sanchez E; Steinberg JA; Baritaki S; Gordon M; Wang C; Shalitin D; Chen H; Pang S; Bonavida B; Said J; Berenson JR
    Br J Haematol; 2007 Aug; 138(4):467-78. PubMed ID: 17587338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma.
    Bahlis NJ; McCafferty-Grad J; Jordan-McMurry I; Neil J; Reis I; Kharfan-Dabaja M; Eckman J; Goodman M; Fernandez HF; Boise LH; Lee KP
    Clin Cancer Res; 2002 Dec; 8(12):3658-68. PubMed ID: 12473574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical activity of arsenic trioxide for the treatment of multiple myeloma.
    Munshi NC; Tricot G; Desikan R; Badros A; Zangari M; Toor A; Morris C; Anaissie E; Barlogie B
    Leukemia; 2002 Sep; 16(9):1835-7. PubMed ID: 12200700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies.
    Douer D; Tallman MS
    J Clin Oncol; 2005 Apr; 23(10):2396-410. PubMed ID: 15800332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arsenic metabolism in multiple myeloma and astrocytoma cells.
    Falnoga I; Slejkovec Z; Pucer A; Podgornik H; Tusek-Znidaric M
    Biol Trace Elem Res; 2007 Apr; 116(1):5-28. PubMed ID: 17634624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma.
    Berenson JR; Matous J; Swift RA; Mapes R; Morrison B; Yeh HS
    Clin Cancer Res; 2007 Mar; 13(6):1762-8. PubMed ID: 17363530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of arsenic trioxide for the treatment of relapsed and refractory multiple myeloma: a systematic review.
    Röllig C; Illmer T
    Cancer Treat Rev; 2009 Aug; 35(5):425-30. PubMed ID: 19464807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JWA is required for arsenic trioxide induced apoptosis in HeLa and MCF-7 cells via reactive oxygen species and mitochondria linked signal pathway.
    Zhou J; Ye J; Zhao X; Li A; Zhou J
    Toxicol Appl Pharmacol; 2008 Jul; 230(1):33-40. PubMed ID: 18387645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The incidence of recurrent herpes simplex and herpes zoster infection during treatment with arsenic trioxide.
    Nouri K; Ricotti CA; Bouzari N; Chen H; Ahn E; Bach A
    J Drugs Dermatol; 2006 Feb; 5(2):182-5. PubMed ID: 16485889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of melphalan, arsenic trioxide, and ascorbic acid combination therapy (MAC) in relapsed and refractory multiple myeloma.
    Borad MJ; Swift R; Berenson JR
    Leukemia; 2005 Jan; 19(1):154-6. PubMed ID: 15496977
    [No Abstract]   [Full Text] [Related]  

  • 17. Arsenic trioxide in multiple myeloma: rationale and future directions.
    Anderson KC; Boise LH; Louie R; Waxman S
    Cancer J; 2002; 8(1):12-25. PubMed ID: 11895198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arsenic trioxide: a new immunomodulatory agent in the management of multiple myeloma.
    Hussein MA
    Med Oncol; 2001; 18(4):239-42. PubMed ID: 11918450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical activity of arsenic trioxide in Burkitt-like lymphoma.
    Ravandi F; van Besien K
    Leukemia; 2003 Jan; 17(1):271-2. PubMed ID: 12529694
    [No Abstract]   [Full Text] [Related]  

  • 20. Arsenic trioxide: new preparation. Acute promyelocytic leukaemia: encouraging results but persistent doubts.
    Prescrire Int; 2004 Aug; 13(72):135-7. PubMed ID: 15532137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.